(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Surveys of Music Collections by Film Stars - 2Manual for Tracking down Spending plan Agreeable Travel Objections
- 3Here's what the Artemis 2 astronauts will be doing on each day of NASA's historic moon mission
- 4Hezbollah claims right to respond to killing of top commander
- 5Astrophotographer captures rare footage of the Hubble Telescope crossing the sun (video)
- Eight arrested in joint Scotland and Spain gang raids
- AfD in Brandenburg takes back suit against the intelligence service
- Administrative building in Sharjah region targeted by Iranian drone, UAE authorities announce
- EU Council president: Ukraine should receive binding guarantees
- Zelensky sees win for Ukraine as EU finally reaches funding deal
- Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- The Specialty of Compromise: Examples from Reality
- Instructions to Clean and Really focus on Your Lab Precious stone
- Baby takes 1st steps after receiving groundbreaking gene-edited therapy
